Corcept Therapeutics
Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CORT Key Statistics
Stock Snapshot
Corcept Therapeutics(CORT) stock is priced at $34.80, giving the company a market capitalization of 3.7B. It carries a P/E multiple of 43.73.
During the trading session on 2026-02-27, Corcept Therapeutics(CORT) shares reached a daily high of $35.64 and a low of $34.59. At a current price of $34.80, the stock is +0.6% higher than the low and still -2.4% under the high.
Trading activity shows a volume of 234.42K, compared to an average daily volume of 2.62M.
The stock's 52-week range extends from a low of $28.66 to a high of $117.33.
The stock's 52-week range extends from a low of $28.66 to a high of $117.33.
CORT News
Corcept Therapeutics (CORT) is back in focus after disclosing a Complete Response Letter from the FDA for relacorilant in Cushing’s syndrome, followed by multip...
Corcept Therapeutics ((CORT)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level...
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67 and keeps a Buy rating on the shar...
Analyst ratings
71%
of 7 ratingsMore CORT News
Multiple shareholder class action lawsuits have been filed against Corcept Therapeutics (NasdaqCM:CORT) after the company disclosed that the FDA issued a Comple...
Reports Q4 revenue $202.1M, consensus $254.94M. “In 2025, our Cushing’s syndrome business experienced a surge in demand due to growing recognition among physici...
Corcept Therapeutics ( (CORT) ) has provided an update. On February 24, 2026, Corcept Therapeutics reported audited fourth-quarter and full-year 2025 results,...
If you are wondering whether Corcept Therapeutics at around US$34.82 is starting to look interesting on price, you are not alone. The stock has been drawing att...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.